The End or a New Era of Development of SARS-CoV-2 Virus: Genetic Variants Responsible for Severe COVID-19 and Clinical Efficacy of the Most Commonly Used Vaccines in Clinical Practice-Reference-Cited by-同舟云学术

The End or a New Era of Development of SARS-CoV-2 Virus: Genetic Variants Responsible for Severe COVID-19 and Clinical Efficacy of the Most Commonly Used Vaccines in Clinical Practice

Published:2023-06-30 Issue:7 Volume:11 Page:1181
ISSN:2076-393X
Container-title:Vaccines
language:en
Short-container-title:Vaccines

Author:

Miteva Dimitrina¹^ORCID,Kitanova Meglena¹^ORCID,Batselova Hristiana²,Lazova Snezhina³⁴^ORCID,Chervenkov Lyubomir⁵^ORCID,Peshevska-Sekulovska Monika⁶⁷^ORCID,Sekulovski Metodija⁷⁸^ORCID,Gulinac Milena⁹,Vasilev Georgi V.¹⁰^ORCID,Tomov Luchesar¹¹^ORCID,Velikova Tsvetelina⁷^ORCID

Affiliation:

1. Department of Genetics, Faculty of Biology, Sofia University “St. Kliment Ohridski”, 8 Dragan Tzankov str., 1164 Sofia, Bulgaria

2. Department of Epidemiology and Disaster Medicine, University Hospital “Saint George”, Medical University, 6000 Plovdiv, Bulgaria

3. Pediatric Department, University Hospital “N. I. Pirogov,” 21 “General Eduard I. Totleben” Blvd, 1606 Sofia, Bulgaria

4. Department of Healthcare, Faculty of Public Health “Prof. Tsekomir Vodenicharov, MD, DSc”, Medical University of Sofia, Bialo More 8 str., 1527 Sofia, Bulgaria

5. Department of Diagnostic Imaging, Medical University Plovdiv, Bul. Vasil Aprilov 15A, 4000 Plovdiv, Bulgaria

6. Department of Gastroenterology, University Hospital Lozenetz, 1407 Sofia, Bulgaria

7. Medical Faculty, Sofia University St. Kliment Ohridski, 1407 Sofia, Bulgaria

8. Department of Anesthesiology and Intensive Care, University Hospital Lozenetz, 1 Kozyak str., 1407 Sofia, Bulgaria

9. Department of General and Clinical Pathology, Medical University of Plovdiv, Bul. Vasil Aprilov 15A, 4000 Plovdiv, Bulgaria

10. Clinic of Endocrinology and Metabolic Disorders, UMHAT “Sv. Georgi”, 4000 Plovdiv, Bulgaria

11. Department of Informatics, New Bulgarian University, Montevideo 21 str., 1618 Sofia, Bulgaria

Abstract

Although the chief of the World Health Organization (WHO) has declared the end of the coronavirus disease 2019 (COVID-19) as a global health emergency, the disease is still a global threat. To be able to manage such pandemics in the future, it is necessary to develop proper strategies and opportunities to protect human life. The data on the SARS-CoV-2 virus must be continuously analyzed, and the possibilities of mutation and the emergence of new, more infectious variants must be anticipated, as well as the options of using different preventive and therapeutic techniques. This is because the fast development of severe acute coronavirus 2 syndrome (SARS-CoV-2) variants of concern have posed a significant problem for COVID-19 pandemic control using the presently available vaccinations. This review summarizes data on the SARS-CoV-2 variants that are responsible for severe COVID-19 and the clinical efficacy of the most commonly used vaccines in clinical practice. The consequences after the disease (long COVID or post-COVID conditions) continue to be the subject of studies and research, and affect social and economic life worldwide.

Funder

European Union-NextGenerationEU

Publisher

MDPI AG

Subject

Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology

Link

https://www.mdpi.com/2076-393X/11/7/1181/pdf

Reference176 articles.

1. COVID-19 2022 update: Transition of the pandemic to the endemic phase;Biancolella;Hum. Genom.,2022

2. (2023, May 29). Statement on the Fifteenth Meeting of the IHR (2005) Emergency Committee on the COVID-19 Pandemic. Available online: https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(COVID-19)-pandemic?adgroupsurvey={adgroupsurvey}&gclid=Cj0KCQjwmtGjBhDhARIsAEqfDEfx3ABO8vnrA5v_oZMuDPL7GkxwtT_jnI2owNdujJfxbZ88TGTwa5caAkZSEALw_wcB.

3. Gong, W., Parkkila, S., Wu, X., and Aspatwar, A. (2022). SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies. Int. Rev. Immunol., 1–22.

4. Centers for Disease Control and Prevention (CDC) (2022, October 10). SARS-CoV-2 Variant Classifications and Definitions (updated 10 June 2021), Available online: https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html.

5. Early approval of COVID-19 vaccines: Pros and cons;Rahman;Hum. Vaccin. Immunother.,2021

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neutralization of Different Variants of SARS-CoV-2 by a F(ab′)2 Preparation from Sera of Horses Immunized with the Viral Receptor Binding Domain;Antibodies;2023-12-07

2. Evaluation of the reasons for the non‑COVID‑19 status: A socio‑demographic analysis;Medicine International;2023-12-05

3. Molecular Mechanisms of Pathogenesis, Prevention, and Therapy of COVID-19: Summarizing the Results of 2022;International Journal of Molecular Sciences;2023-11-08

4. Applications of time series analysis in epidemiology: Literature review and our experience during COVID-19 pandemic;World Journal of Clinical Cases;2023-10-16

5. In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1;Vaccines;2023-09-28